|
|
Volumn 35, Issue 19, 2017, Pages 2125-2132
|
|
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRENTUXIMAB VEDOTIN;
PEMBROLIZUMAB;
PROGRAMMED DEATH 1 LIGAND 1;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
ACUTE GRAFT VERSUS HOST DISEASE;
ADULT;
AGED;
ALLOGENEIC STEM CELL TRANSPLANTATION;
ANEMIA;
ARTHRALGIA;
ARTICLE;
ASTHENIA;
AUTOLOGOUS STEM CELL TRANSPLANTATION;
BACKACHE;
BRONCHITIS;
CANCER GROWTH;
CAUSE OF DEATH;
CHILL;
CLASSICAL HODGKIN LYMPHOMA;
COHORT ANALYSIS;
CONSTIPATION;
COUGHING;
CYTOKINE RELEASE SYNDROME;
DIARRHEA;
DRUG EFFICACY;
DRUG SAFETY;
DYSPNEA;
FATIGUE;
FEMALE;
FEVER;
FOLLOW UP;
HEADACHE;
HEALTH STATUS;
HUMAN;
HYPOTHYROIDISM;
IMMUNOHISTOCHEMISTRY;
INFUSION RELATED REACTION;
INSOMNIA;
MAJOR CLINICAL STUDY;
MALE;
MUSCLE SPASM;
MYALGIA;
MYELITIS;
MYOCARDITIS;
MYOSITIS;
NAUSEA;
NEUTROPENIA;
NOSE OBSTRUCTION;
OROPHARYNX PAIN;
PATIENT-REPORTED OUTCOME;
PHASE 2 CLINICAL TRIAL;
PNEUMONIA;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PRURITUS;
RASH;
RHINOPHARYNGITIS;
SALVAGE THERAPY;
SEPTIC SHOCK;
SINUSITIS;
TREATMENT DURATION;
TREATMENT RESPONSE;
TUMOR VOLUME;
UPPER RESPIRATORY TRACT INFECTION;
URINARY TRACT INFECTION;
VOMITING;
CLINICAL TRIAL;
HODGKIN DISEASE;
MIDDLE AGED;
MULTICENTER STUDY;
RECURRENT DISEASE;
YOUNG ADULT;
ADULT;
AGED;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
COHORT STUDIES;
FEMALE;
HODGKIN DISEASE;
HUMANS;
MALE;
MIDDLE AGED;
RECURRENCE;
YOUNG ADULT;
|
|
EID: 85021757660
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2016.72.1316 Document Type: Article |
|
Times cited : (806)
|
|
References (18)
|
